AGIO · Insider Trading
Agios Pharmaceuticals, Inc.
Every open-market purchase and sale reported by AGIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-23 | Sarah Gheuens | Chief Medical Officer | MIXED | — | −$24.90K |
| 2026-08-06 | Sarah Gheuens | Chief Medical Officer | Sell | −30,000 | −$914.40K |
| 2026-08-06 | Sarah Gheuens | Chief Medical Officer | Sell | −30,000 | −$914.40K |
| 2026-07-10 | Jay T. Backstrom | Director | A | +1,447 | — |
| 2026-07-02 | Sarah Gheuens | Chief Medical Officer | MIXED | +4,368 | −$150.50K |
| 2026-06-23 | Adams Catherine Owen | Director | M | +2,816 | — |
| 2026-06-23 | Jay T. Backstrom | Director | A | +17,877 deriv. | — |
| 2026-06-23 | Krishnan Viswanadhan | Chief Strategy and Operations | MIXED | — | — |
| 2026-06-23 | Sarah Gheuens | Chief Medical Officer | MIXED | — | — |
| 2026-06-23 | Cecilia Jones | Chief Financial Officer | MIXED | — | — |
| 2026-06-23 | Brian Goff | Chief Executive Officer | MIXED | — | — |
| 2026-06-23 | Jacqualyn A Fouse | Director | M | +2,816 | — |
| 2026-06-23 | Rahul D. Ballal | Director | M | +2,816 | — |
| 2026-06-23 | James William Burns | Chief Legal Officer | MIXED | — | — |
| 2026-06-23 | David Scadden | Director | M | +2,816 | — |
| 2026-06-23 | Cynthia Smith | Director | M | +2,816 | — |
| 2026-06-23 | Jeffrey D Capello | Director | M | +2,816 | — |
| 2026-06-23 | Kaye I Foster-Cheek | Director | M | +2,816 | — |
| 2026-06-23 | Maykin Ho | Director | M | +2,816 | — |
| 2026-06-23 | Tsveta Milanova | Chief Commercial Officer | MIXED | — | — |
| 2026-06-16 | Adams Catherine Owen | Director | M | +1,976 | — |
| 2026-06-16 | Jeffrey D Capello | Director | M | +1,976 | — |
| 2026-04-06 | Tsveta Milanova | Chief Commercial Officer | MIXED | +5,238 | −$113.22K |
| 2026-04-06 | James William Burns | Chief Legal Officer | MIXED | +5,220 | −$113.85K |
| 2026-04-06 | Cecilia Jones | Chief Financial Officer | MIXED | +5,359 | −$109.02K |
| 2026-04-06 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | MIXED | +5,141 | −$102.71K |
| 2026-04-06 | Brian Goff | Chief Executive Officer | MIXED | +19,960 | −$661.85K |
| 2026-04-06 | Sarah Gheuens | Chief Medical Officer | MIXED | +5,560 | −$102.05K |
| 2026-03-09 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | MIXED | +5,141 | −$82.26K |
| 2026-03-05 | Theodore James Washburn Jr. | Principal Accounting Officer | Sell | −5,272 | −$152.26K |
| 2026-03-03 | Krishnan Viswanadhan | Chief Corp Dev & Strategy | A | +66,000 deriv. | — |
| 2026-03-03 | Theodore James Washburn Jr. | Principal Accounting Officer | MIXED | +5,272 | −$64.38K |
| 2026-03-03 | Cecilia Jones | Chief Financial Officer | MIXED | +11,934 | −$145.81K |
| 2026-03-03 | James William Burns | Chief Legal Officer | MIXED | +12,368 | −$151.11K |
| 2026-03-03 | Sarah Gheuens | Chief Medical Officer | MIXED | +9,611 | −$117.43K |
| 2026-03-03 | Brian Goff | Chief Executive Officer | MIXED | +21,445 | −$522.87K |
| 2026-03-03 | Tsveta Milanova | Chief Commercial Officer | MIXED | +6,798 | −$83.06K |
| 2026-01-07 | Tsveta Milanova | Chief Commercial Officer | MIXED | +5,603 | −$77.60K |
| 2026-01-02 | Sarah Gheuens | Chief Medical Officer | MIXED | +3,068 | −$79.43K |
| 2026-01-02 | James William Burns | Chief Legal Officer | MIXED | +3,068 | −$79.43K |
| 2026-01-02 | Tsveta Milanova | Chief Commercial Officer | MIXED | +3,068 | −$79.43K |
| 2026-01-02 | Cecilia Jones | Chief Financial Officer | MIXED | +3,068 | −$79.43K |
| 2026-01-02 | Brian Goff | Chief Executive Officer | MIXED | +19,575 | −$506.66K |
| 2025-11-14 | David Scadden | Director | MIXED | — | −$5.15K |
| 2025-11-13 | Sarah Gheuens | Chief Medical Officer | MIXED | — | −$46.06K |
| 2025-11-03 | Sarah Gheuens | Chief Medical Officer | MIXED | — | −$3.76K |
| 2025-10-29 | Sarah Gheuens | Chief Medical Officer | MIXED | — | −$62.44K |
| 2025-10-10 | David Scadden | Director | MIXED | — | −$4.58K |
| 2025-10-02 | David Scadden | Director | MIXED | — | −$4.38K |
| 2025-09-30 | Cecilia Jones | Chief Financial Officer | MIXED | +3,821 | −$134.25K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Brian Goff | Chief Executive Officer | 177,604 | $6.54M |
| Jacqualyn A Fouse | Director | 154,156 | $5.68M |
| Sarah Gheuens | Chief Medical Officer | 55,145 | $2.03M |
| Cecilia Jones | Chief Financial Officer | 54,998 | $2.03M |
| James William Burns | Chief Legal Officer | 52,586 | $1.94M |
| Tsveta Milanova | Chief Commercial Officer | 50,091 | $1.85M |
| David Scadden | Director | 20,419 | $752.44K |
| Maykin Ho | Director | 19,848 | $731.40K |
| Cynthia Smith | Director | 15,230 | $561.23K |
| Rahul D. Ballal | Director | 15,230 | $561.23K |
| Kaye I Foster-Cheek | Director | 12,484 | $460.04K |
| Jeffrey D Capello | Director | 10,865 | $400.38K |
| Adams Catherine Owen | Director | 10,865 | $400.38K |
| Krishnan Viswanadhan | Chief Strategy and Operations | 10,282 | $378.89K |
| Jay T. Backstrom | Director | 1,447 | $53.32K |
| Theodore James Washburn Jr. | Principal Accounting Officer | 868 | $31.99K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AGIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.